The GLP-1 gold rush has turned Novo Nordisk and Eli Lilly into the most valuable companies in Europe and the most talked-about names on Wall Street.
But while everyone debates who's taking Ozempic and who's secretly on Zepbound, almost nobody is asking the question that actually matters: what happens when a drug becomes a subscription?
These aren't antibiotics you take for ten days and forget.
GLP-1s are designed to be taken indefinitely.
Stop the injection, and the appetite comes roaring back.
That's not a side effect — that's the business model.
Analysts project the GLP-1 market could hit $150 billion annually within a decade.
That's bigger than the entire global movie industry, the music industry, and professional sports combined.
And unlike a movie ticket, you have to keep buying this product every single month or the benefits vanish.
Here's where the dots connect in a way the mainstream press keeps missing.
Novo Nordisk and Eli Lilly have spent years quietly shaping the narrative through patient advocacy groups, medical conferences, and social media influencers.
Telehealth startups like Hims & Hers and Ro built entire business lines overnight by prescribing compounded versions.
WeightWatchers, desperate to stay relevant, bought a telehealth company just to get in on the action.
The active ingredient, semaglutide, is produced through a complex fermentation process that few facilities on Earth can handle.
When shortages hit in 2022 and 2023, instead of expanding access, the FDA allowed compounding pharmacies to fill the gap — then reversed course once Big Pharma's supply caught up.
Walmart and Costco have both reported that grocery sales are dipping in areas with high GLP-1 adoption.
Nestlé launched a line of "companion" frozen meals specifically for people on the drugs.
The entire consumer economy is rearranging itself around a shot.
But the most underreported angle is the data.
Every prescription generates a treasure trove of information — weight, blood sugar, eating patterns, insurance claims, even shopping behavior when linked to loyalty programs.
That data is worth billions to insurers, employers, and marketers.
You're a stream of recurring revenue and behavioral insights.
Meanwhile, the long-term safety picture remains genuinely uncertain.
We have years of data on diabetics, but millions of otherwise healthy people are now using these drugs for weight loss.
Muscle loss, nutritional deficiencies, and potential pancreatic issues are all being studied.
The FDA recently added a warning about severe stomach paralysis.
None of this means the drugs are dangerous for everyone — but it does mean the full story is still being written.
The real question isn't whether GLP-1s work.
The question is who controls the narrative, who profits from the dependency, and who gets left holding the bill when the music stops. **My take:** GLP-1s are a genuine medical breakthrough wrapped inside a business model that profits from never letting you leave.
That doesn't make them evil — it makes them a perfect example of American healthcare's core incentive: treat forever, charge forever.
Final Thoughts
Stay curious about the cure, but stay woke about the contract.